Dr. Loaiza-Bonilla on Right- Versus Left-Sided Colorectal Cancer

Video

Arturo Loaiza-Bonilla, MD, medical oncologist, specialized in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses findings of patients with right- versus left-sided tumors of colorectal cancer (CRC).

Arturo Loaiza-Bonilla, MD, medical oncologist, specialized in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses findings of patients with right- versus left-sided tumors of colorectal cancer (CRC).

Among the 250 samples from the University of Pennsylvania, there were 2 common genomic alterations that were statistically significant. The first was BRAF, which tends to have a worse prognosis compared with BRAF wild-type CRCs. The second was CTNNB1, which is a ubiquitin mutation.

Most of the phase II and III clinical trials had not included next-generation sequencing as part of the biomarker test, due to more costly technologies and uncertainty as to which biomarkers are appropriate to test, explains Loaiza-Bonilla.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine